Keck School Faculty

Danieli B. Salinas, MD
Danieli B. Salinas, MD
Associate Professor of Clinical Pediatrics
Pediatrics
4640 West Sunset Boulevard Off Campus Los Angeles
I am originally from Rio de Janeiro, Brazil and I came to the U.S. for Residency and Fellowship training in Pediatric Pulmonology with the goal of becoming a physician scientist. My passion is Cystic Fibrosis. I enjoy taking care of these complex children and I am fascinated by the science behind the consequences of this defective chloride channel. The fact that we still don’t have a cure for this disease and that there are nearly 2,000 different mutations producing a wide range of clinical presentations are my biggest motivation to work in this field. I hope to make contributions to improve the lives of people with this disease and I hope I can one day say CF stands for Cure Found! My major areas of research interest are predicting clinical outcomes in children with a positive newborn screening for Cystic Fibrosis.
a. Retrospective study based on the California database.
b. Hierarchical modeling of clinical prediction.
c. Developing a Sweat Rate test for infants for more accurately diagnose CF and predict clinical outcome.

Abnormal Lung Clearance Index in Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Children with Otherwise Normal FEV1 Lung. 2020 Feb; 198(1):163-167. . View in PubMed

Image-based ß-adrenergic sweat rate assay captures minimal cystic fibrosis transmembrane conductance regulator function Pediatr Res. 2020 Jan; 87(1):137-145. . View in PubMed

Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition J Cyst Fibros. 2019 Nov; 18(6):778-780. . View in PubMed

The increasing challenge of genetic counseling for cystic fibrosis J Cyst Fibros. 2019 03; 18(2):167-174. . View in PubMed

Low Beta-Adrenergic Sweat Responses in Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome Children Pediatr Allergy Immunol Pulmonol. 2017 Mar 01; 30(1):2-6. . View in PubMed

Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate DiagnosesJ Pediatr. 2017 02; 181S:S27-S32. e1. . View in PubMed

Phenotypes of California CF Newborn Screen-Positive Children with CFTR 5T Allele by TG Repeat Length Genet Test Mol Biomarkers. 2016 Sep; 20(9):496-503. . View in PubMed

Benign and Deleterious Cystic Fibrosis Transmembrane Conductance Regulator Mutations Identified by Sequencing in Positive Cystic Fibrosis Newborn Screen Children from California PLoS One. 2016; 11(5):e0155624. . View in PubMed

Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants J Cyst Fibros. 2015 Nov; 14(6):714-9. . View in PubMed

Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California J Mol Diagn. 2013 Sep; 15(5):710-22. . View in PubMed

Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis Am J Physiol Cell Physiol. 2006 Mar; 290(3):C741-9. . View in PubMed

Submucosal gland dysfunction as a primary defect in cystic fibrosis FASEB J. 2005 Mar; 19(3):431-3. . View in PubMed

CFTR involvement in nasal potential differences in mice and pigs studied using a thiazolidinone CFTR inhibitor Am J Physiol Lung Cell Mol Physiol. 2004 Nov; 287(5):L936-43. . View in PubMed

Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models J Biol Chem. 2004 Sep 24; 279(39):40629-33. . View in PubMed

Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy J Gen Physiol. 2004 Aug; 124(2):125-37. . View in PubMed

Powered by SC CTSI
Go to Top